SG11202109191SA - Macrocyclic compounds as sting agonists - Google Patents
Macrocyclic compounds as sting agonistsInfo
- Publication number
- SG11202109191SA SG11202109191SA SG11202109191SA SG11202109191SA SG11202109191SA SG 11202109191S A SG11202109191S A SG 11202109191SA SG 11202109191S A SG11202109191S A SG 11202109191SA SG 11202109191S A SG11202109191S A SG 11202109191SA SG 11202109191S A SG11202109191S A SG 11202109191SA
- Authority
- SG
- Singapore
- Prior art keywords
- macrocyclic compounds
- sting agonists
- sting
- agonists
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921012258 | 2019-03-28 | ||
| IN201921046194 | 2019-11-13 | ||
| PCT/IB2020/052654 WO2020194160A1 (en) | 2019-03-28 | 2020-03-21 | Macrocyclic compounds as sting agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109191SA true SG11202109191SA (en) | 2021-09-29 |
Family
ID=70293003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109191SA SG11202109191SA (en) | 2019-03-28 | 2020-03-21 | Macrocyclic compounds as sting agonists |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220144852A1 (ja) |
| EP (1) | EP3946610A1 (ja) |
| JP (1) | JP2022527306A (ja) |
| KR (1) | KR20210146370A (ja) |
| CN (1) | CN113631228B (ja) |
| AU (1) | AU2020245263A1 (ja) |
| BR (1) | BR112021018947A2 (ja) |
| CA (1) | CA3132508A1 (ja) |
| CL (1) | CL2021002480A1 (ja) |
| CO (1) | CO2021012559A2 (ja) |
| CR (1) | CR20210495A (ja) |
| EC (1) | ECSP21071644A (ja) |
| IL (1) | IL286526A (ja) |
| MA (1) | MA55517A (ja) |
| MX (1) | MX2021011686A (ja) |
| PE (1) | PE20220169A1 (ja) |
| SG (1) | SG11202109191SA (ja) |
| WO (1) | WO2020194160A1 (ja) |
| ZA (1) | ZA202106629B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022001125A2 (pt) * | 2019-07-22 | 2022-03-15 | Lupin Ltd | Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos |
| JP2022543086A (ja) | 2019-08-02 | 2022-10-07 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物 |
| KR20220167275A (ko) | 2020-04-10 | 2022-12-20 | 오노 야꾸힝 고교 가부시키가이샤 | 암 치료 방법 |
| JP2024503508A (ja) * | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体－薬物コンジュゲート |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| JP6835727B2 (ja) * | 2015-02-05 | 2021-02-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｉｒａｋ１／４阻害剤としての大環状化合物及びその使用 |
| EP3325473A4 (en) | 2015-07-22 | 2019-06-26 | The Royal Institution for the Advancement of Learning / McGill University | Compounds and uses thereof in the treatment of cancer and other medical disorders |
| AR107032A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| CN109608443B (zh) | 2016-04-07 | 2021-09-07 | 葛兰素史密斯克莱知识产权发展有限公司 | 用作蛋白质调节剂的杂环酰胺 |
| EA201892128A1 (ru) | 2016-04-07 | 2019-04-30 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| EP3642184A1 (en) | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Small molecule modulators of human sting |
| SG11201912397RA (en) | 2017-06-22 | 2020-01-30 | Curadev Pharma Ltd | Small molecule modulators of human sting |
| JP7274478B2 (ja) | 2017-07-27 | 2023-05-16 | スティングレイ・セラピューティクス・インコーポレイテッド | 置換された－３Ｈ－イミダゾ［４，５－ｃ］ピリジン及び１Ｈ－ピロロ［２，３－ｃ］ピリジンシリーズの新規なエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ－１（ＥＮＰＰ１）並びにがん免疫治療薬としてのインターフェロン遺伝子（ＳＴＩＮＧ）モジュレータのための刺激剤 |
| EP3661498A4 (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT |
| US11312772B2 (en) * | 2017-08-04 | 2022-04-26 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment |
-
2020
- 2020-03-21 EP EP20719719.5A patent/EP3946610A1/en active Pending
- 2020-03-21 SG SG11202109191SA patent/SG11202109191SA/en unknown
- 2020-03-21 BR BR112021018947A patent/BR112021018947A2/pt unknown
- 2020-03-21 JP JP2021557830A patent/JP2022527306A/ja active Pending
- 2020-03-21 PE PE2021001577A patent/PE20220169A1/es unknown
- 2020-03-21 US US17/598,524 patent/US20220144852A1/en active Pending
- 2020-03-21 AU AU2020245263A patent/AU2020245263A1/en active Pending
- 2020-03-21 CN CN202080025785.1A patent/CN113631228B/zh active Active
- 2020-03-21 CR CR20210495A patent/CR20210495A/es unknown
- 2020-03-21 KR KR1020217035108A patent/KR20210146370A/ko unknown
- 2020-03-21 CA CA3132508A patent/CA3132508A1/en active Pending
- 2020-03-21 MX MX2021011686A patent/MX2021011686A/es unknown
- 2020-03-21 MA MA055517A patent/MA55517A/fr unknown
- 2020-03-21 WO PCT/IB2020/052654 patent/WO2020194160A1/en active Application Filing
-
2021
- 2021-09-08 ZA ZA2021/06629A patent/ZA202106629B/en unknown
- 2021-09-19 IL IL286526A patent/IL286526A/en unknown
- 2021-09-24 CO CONC2021/0012559A patent/CO2021012559A2/es unknown
- 2021-09-24 EC ECSENADI202171644A patent/ECSP21071644A/es unknown
- 2021-09-24 CL CL2021002480A patent/CL2021002480A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202106629B (en) | 2022-07-27 |
| CO2021012559A2 (es) | 2021-09-30 |
| JP2022527306A (ja) | 2022-06-01 |
| KR20210146370A (ko) | 2021-12-03 |
| AU2020245263A1 (en) | 2021-10-07 |
| CA3132508A1 (en) | 2020-10-01 |
| IL286526A (en) | 2021-10-31 |
| MX2021011686A (es) | 2021-10-22 |
| ECSP21071644A (es) | 2021-12-30 |
| CN113631228A (zh) | 2021-11-09 |
| PE20220169A1 (es) | 2022-01-28 |
| BR112021018947A2 (pt) | 2022-02-08 |
| CR20210495A (es) | 2021-10-18 |
| CL2021002480A1 (es) | 2022-04-29 |
| CN113631228B (zh) | 2023-10-13 |
| MA55517A (fr) | 2022-02-09 |
| US20220144852A1 (en) | 2022-05-12 |
| WO2020194160A1 (en) | 2020-10-01 |
| EP3946610A1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3774765A4 (en) | Aza-benzothiophene compounds as sting agonists | |
| EP3621624A4 (en) | CYCLIC DINUCLEOTIDIC COMPOUNDS AS STING AGONISTS | |
| HK1249109A1 (zh) | 作為sting激動劑的環狀二核苷酸化合物 | |
| EP3727401A4 (en) | CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS | |
| IL286526A (en) | Macrocyclic compounds as sting agonists | |
| IL286102A (en) | macrocyclic compounds | |
| ZA202201375B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| GB201905721D0 (en) | Compounds | |
| EP3773566A4 (en) | OX2R CONNECTIONS | |
| EP3873484C0 (en) | NEW STING AGONISTS | |
| PL3601253T3 (pl) | Nowe hamujące ptefb związki makrocykliczne | |
| EP3891166A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS USED AS STING AGONISTS | |
| GB201910305D0 (en) | Compounds | |
| EP3891164A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| EP3891165A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| GB201908536D0 (en) | Compounds | |
| GB201910304D0 (en) | Compounds | |
| GB201908171D0 (en) | Compounds | |
| GB201908095D0 (en) | Carboxy-MIDA-boronate compounds | |
| GB201715210D0 (en) | Macrocyclic compounds | |
| GB201910484D0 (en) | Context search for unstructiured content | |
| GB201912850D0 (en) | Compounds | |
| GB201911848D0 (en) | Compounds | |
| GB201910885D0 (en) | Compounds | |
| GB201910608D0 (en) | Compounds |